Genes in inflammatory bowel disease: Lessons from complex diseases

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 11, Issue 1, 2011, Pages 8-10

  Henderson, Paul ^a   Satsangi, Jack ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; JANUS KINASE 2; LEUCINE RICH REPEAT KINASE 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAT3 PROTEIN;

ATG16L1 GENE; CROHN DISEASE; DIZYGOTIC TWINS; EDITORIAL; ENTERITIS; ETHNIC DIFFERENCE; GENE; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; ICOSLG GENE; IMMUNE RESPONSE; MONOZYGOTIC TWINS; NONHUMAN; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS; GENETICS; HUMAN GENOME PROJECT; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PHENOTYPE; POPULATION GENETICS;

GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMAN GENOME PROJECT; HUMANS; INFLAMMATORY BOWEL DISEASES; PHENOTYPE;

EID: 79958029177     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.11-1-8     Document Type: Editorial

References (38)

1. Vatn MH. Natural history and complications of IBD. Curr Gastroenterol Rep 2009;11:481-7.
2. Shivananda S, Lennard-Jones J, Logan R et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7. (Pubitemid 26426470)
3. Bernstein CN,Wajda A, Svenson LW et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-68. (Pubitemid 43980630)
4. Van Limbergen J,Wilson D, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009;10:89-116.
5. Armitage EL, Aldhous MC, Anderson N et al. Incidence of juvenileonset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology 2004;127:1051-7. (Pubitemid 39345874)
6. Sokol H, Seksik P. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Curr Opin Gastroenterol 2010;26:327-31.
7. Dalziel TK. Chronic interstitial enteritis. BMJ 1913;(ii):1068-70.
8. Crohn BB, Ginsburg L, Oppenheimer GD. Regional ileitis: a clinical and pathologic entity. JAMA 1932;99:1323-9.
9. Peeters M, Nevens H, Baert F et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996;111:597-603. (Pubitemid 26293222)
10. Roth MP, Petersen GM, McElree C et al. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology 1989;96:1016-20. (Pubitemid 19091115)
11. Lees CW, Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009;3:513-34.
12. Tysk C, Lindberg E, Jarnerot G et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-6.
13. Russell RK, Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol 2004;18:525-39. (Pubitemid 38667464)
14. Noble C, Nimmo E, Gaya D et al. Novel susceptibility genes in inflammatory bowel disease.World J Gastroenterol 2006;12:1991-9.
15. Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3. (Pubitemid 26067722)
16. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603. (Pubitemid 32531408)
17. Henderson P, Van Limbergen J,Wilson DC et al. Genetics of childhood- onset inflammatory bowel disease. Inflamm Bowel Dis 2010;17:346-61.
18. Lala S, Ogura Y, Osborne C et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003;125:47-57. (Pubitemid 36799106)
19. Kelsall B. Getting to the guts of NOD2. Nat Med 2005;11:383-4. (Pubitemid 40562327)
20. Petnicki-Ocwieja T, Hrncir T, Liu YJ et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A 2009;106:15813-8.
21. Rahman MK,Midtling EH, Svingen PA et al. The Pathogen Recognition Receptor NOD2 Regulates Human FOXP3+ T Cell Survival. J Immunol 2010;184:7247-56.
22. Sabbah A, Chang TH, Harnack R et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009;10:1073-80.
23. International HapMap Project. Database of genes associated with human disease and response to pharmaceuticals [HapMap web site]. www.hapmap.org
24. Franke A, McGovern DP, Barrett JC et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25.
25. Mathew CG. New links to the pathogenesis of Crohn's disease provided by genome-wide association scans. Nat Rev Genet 2008;9:9-14. (Pubitemid 350277296)
26. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-62.
27. Cadwell K, Liu JY, Brown SL et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008;456:259-63.
28. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3. (Pubitemid 44871953)
29. Cooney R, Baker J, Brain O et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010;16:90-7.
30. Travassos LH, Carneiro LA, Ramjeet M et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010;11:55-62.
31. Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79. (Pubitemid 39482500)
32. Massey DC, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008;57:1294-6.
33. Farkas S, Hornung M, Sattler C et al. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis 2006;21:747-53. (Pubitemid 44524028)
34. Latiano A, Palmieri O, Corritore G et al. Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1108-17.
35. Jurgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R Genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010;105:1811-9.
36. Peeters H, Bogaert S, Laukens D et al. CARD15 variants determine a disturbed early response of monocytes to adherent-invasive Escherichia coli strain LF82 in Crohn's disease. Int J Immunogenet 2007;34:181-91. (Pubitemid 46763548)
37. Kirkwood CD,Wagner J, Boniface K et al. Mycobacterium avium subspecies paratuberculosis in children with early-onset Crohn's disease. Inflamm Bowel Dis 2009;15:1643-55.
38. Aldhous MC, Prescott RJ, Roberts S et al. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease? Inflamm Bowel Dis 2008;14:1469-82.